Does lower fibrin clot permeability predict increased risk of stroke and bleeding in patients with atrial fibrillation on vitamin K antagonists?
Formation of denser fibrin networks (lower clot permeability) independently predicts both thromboembolic and major bleeding risks in atrial fibrillation patients on vitamin K antagonists.
Background and Purpose— Formation of denser fiber networks has been reported in atrial fibrillation and ischemic stroke. In this longitudinal cohort study, we evaluated whether fibrin clot density may predict thromboembolic and bleeding risk in patients with atrial fibrillation on vitamin K antagonists. Methods— In 236 patients with atrial fibrillation receiving vitamin K antagonists treatment, we measured ex vivo plasma clot permeability (K s ), a measure of the pore size in fibrin networks. Results— During a median follow-up of 4.3 (interquartile range, 3.7–4.8) years, annual rates of ischemic stroke or transient ischemic attack and major bleeds were 2.96% and 3.45%, respectively. In multivariate Cox regression analysis, patients with lower K s (<6.8 cm 2 ×10 −9 , median) had increased risk of ischemic stroke or transient ischemic attack (hazard ratio HR, 6.55; 95% confidence interval CI, 2.17–19.82) and major bleeds (HR, 10.65; 95% CI, 3.52–32.22). Patients with elevated K s (≥6.8 cm 2 ×10 −9 ) had an increased rate of minor bleeding compared with the remainder (11.63% per year versus 3.55% per year; P <0.0001). The independent predictors of stroke or transient ischemic attack were low K s (<6.8 cm 2 ×10 − 9 ; HR, 7.24; 95% CI, 2.53–20.76), age (HR, 1.05; 95% CI, 1.01–1.10), and treatment with angiotensin-converting enzyme inhibitors (HR, 2.27; 95% CI, 1.08–4.77). Major bleeds were predicted by low K s (<6.8 cm 2 ×10 −9 ; HR, 8.48; 95% CI, 2.99–24.1) and HAS-BLED score ≥3 (HR, 2.22; 95% CI, 1.12–4.38). Conclusions— This study is the first to show that unfavorable fibrin properties reflected by formation of denser fibrin networks determine, in part, the efficacy and safety of anticoagulation with vitamin K antagonists in patients with atrial fibrillation.
Drabik et al. (Thu,) studied this question.